Improving access to Alzheimer's treatment for African American and white patients in Alabama
Official title: EQUITY IN ACCESS TO ALZHEIMER'S DISEASE PHARMACOLOGIC TREATMENT FOR AFRICAN AMERICAN AND WHITE PATIENTS IN ALABAMA A MIXED METHODS STUDY TO INFORM RECOMMENDATIONS EquAAL
Funded at University of Alabama at Birmingham · NIH-10976201 · Data updated 2026-11-12
This study is looking at the challenges that African American and white patients in Alabama encounter when trying to access new Alzheimer's treatments, like lecanemab, and aims to find ways to make these treatments easier and fairer for everyone to get.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | August 15, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $297,000 |
| NIH project number | 1R61AG088966-01 |
| Project ID | NIH-10976201 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are African American and white patients aged 65 and older who are affected by Alzheimer's disease and reside in Alabama.
✕Less likely to help
Patients outside of Alabama or those not affected by Alzheimer's disease may not benefit from this research.
What this research studies
This research investigates the barriers that African American and white patients in Alabama face in accessing new Alzheimer's disease treatments, such as lecanemab. It aims to understand the full costs associated with these treatments, including copayments, specialist visits, and travel expenses. By conducting qualitative analyses, the study will explore the availability, accessibility, affordability, and overall perceived value of these new drugs. The goal is to develop recommendations for equitable access to care for older adults affected by Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could lead to improved access to effective Alzheimer's treatments for underserved populations, ultimately enhancing patient outcomes.
How similar studies have gone: Previous research has shown that addressing access disparities in healthcare can lead to improved treatment outcomes, suggesting that this approach may be effective.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Pisu, Maria — University of Alabama at Birmingham
- Study coordinator: Pisu, Maria
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.